secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexaria Bioscience Corp. (LEXX)
CIK:        0001348362
Form:       8-K
Filed at:   2024-07-17T23:59:59+00:00
Accession:  0001640334-24-001132
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexaria animal study interim results: DehydraTECH liraglutide and CBD show weight loss; CFO Cabatuan resigns
--------------------------------------------------------------------------------

- CFO Nelson Cabatuan resigned effective July 15; becomes Chief Strategic Financial Advisor; 150k unvested options expire, vested 50k options reduced to July 2026.
- In study WEIGHT-A24-1, DehydraTECH-CBD3 and DehydraTECH-liraglutide showed largest weight loss: -1.50% and -1.58% over 28 days.
- DehydraTECH works with semaglutide both with and without SNAC; pure semaglutide arm performed similarly to reformulated Rybelsus.
- Dosing in final four study arms (Cohort 2) began, combining DehydraTECH-semaglutide+CBD and DehydraTECH-liraglutide+CBD; results expected mid-October.
- Study is exploratory; not powered for statistical significance; blood glucose and PK data pending.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348362/000164033424001132/0001640334-24-001132-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348362/000164033424001132/lxrp_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-24-001132

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer